Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Feb;52(2):110–114. doi: 10.1136/ard.52.2.110

Antinuclear antibodies in routine analysis: the relevance of putative clinical associations.

A J Swaak 1, V Huysen 1, R J Smeenk 1
PMCID: PMC1004988  PMID: 8447690

Abstract

Defined antinuclear antibodies (ANA), such as antibodies to Ro/SS-A, La/SS-B, Sm, and nRNP, are often present in serum samples from patients with systemic lupus erythematosus (SLE) or other connective tissue diseases (CTD). Most data on associations between the presence of these antibodies and defined disease features have been obtained with the use of predefined groups of patients. In this work the issue of disease associations was approached from a different angle: patients suspected of having CTD were selected on the presence of these ANA in their serum samples and clinical data were subsequently scored according to a defined protocol. It was then tried to relate measured ANA and clinical symptoms. No correlation was observed between the presence of antibodies to Ro/SS-A and specific clinical symptoms. The presence of antibodies to La/SS-B was associated with the diagnosis of Sjögren's syndrome combined with leukocytopenia. In patients positive for antibodies to Sm a significantly increased incidence of skin lesions, such as butterfly rashes and discoid lesions, was seen, together with signs of myocarditis. Myocarditis was also found to be associated with the presence of antibodies to nRNP. The data presented in this study show that previously reported associations of these ANA with clinical symptoms are not confirmed when unselected patients are used.

Full text

PDF
110

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barada F. A., Jr, Andrews B. S., Davis J. S., 4th, Taylor R. P. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum. 1981 Oct;24(10):1236–1244. doi: 10.1002/art.1780241003. [DOI] [PubMed] [Google Scholar]
  2. Beaufils M., Kouki F., Mignon F., Camus J. P., Morel-Maroger L., Richet G. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med. 1983 Feb;74(2):201–205. doi: 10.1016/0002-9343(83)90612-5. [DOI] [PubMed] [Google Scholar]
  3. Boire G., Ménard H. A. Clinical significance of anti-Ro(SSA) antibody in rheumatoid arthritis. J Rheumatol. 1988 Mar;15(3):391–394. [PubMed] [Google Scholar]
  4. Clotet B., Guardia J., Pigrau C., Lience E., Murcia C., Pujol R., Bacardí R. Incidence and clinical significance of anti-ENA antibodies in systemic lupus erythematosus. Estimation by counterimmunoelectrophoresis. Scand J Rheumatol. 1984;13(1):15–20. doi: 10.3109/03009748409102662. [DOI] [PubMed] [Google Scholar]
  5. Fox R. I., Robinson C. A., Curd J. G., Kozin F., Howell F. V. Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum. 1986 May;29(5):577–585. doi: 10.1002/art.1780290501. [DOI] [PubMed] [Google Scholar]
  6. Hamilton R. G., Harley J. B., Bias W. B., Roebber M., Reichlin M., Hochberg M. C., Arnett F. C. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum. 1988 Apr;31(4):496–505. doi: 10.1002/art.1780310406. [DOI] [PubMed] [Google Scholar]
  7. Hochberg M. C., Dorsch C. A., Feinglass E. J., Stevens M. B. Survivorship in systemic lupus erythematosus: effect of antibody to extractable nuclear antigen. Arthritis Rheum. 1981 Jan;24(1):54–59. doi: 10.1002/art.1780240109. [DOI] [PubMed] [Google Scholar]
  8. Kurata N., Tan E. M. Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum. 1976 May-Jun;19(3):574–580. doi: 10.1002/art.1780190309. [DOI] [PubMed] [Google Scholar]
  9. Lee L. A. Anti-Ro (SSA) and anti-La (SSB) antibodies in lupus erythematosus and in Sjögren's syndrome. Arch Dermatol. 1988 Jan;124(1):61–62. [PubMed] [Google Scholar]
  10. Machado M. V., Tynan M. J., Curry P. V., Allan L. D. Fetal complete heart block. Br Heart J. 1988 Dec;60(6):512–515. doi: 10.1136/hrt.60.6.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Maddison P. J., Isenberg D. A., Goulding N. J., Leddy J., Skinner R. P. Anti La(SSB) identifies a distinctive subgroup of systemic lupus erythematosus. Br J Rheumatol. 1988 Feb;27(1):27–31. doi: 10.1093/rheumatology/27.1.27. [DOI] [PubMed] [Google Scholar]
  12. Maddison P. J., Mogavero H., Reichlin M. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. J Rheumatol. 1978 Winter;5(4):407–411. [PubMed] [Google Scholar]
  13. Parker M. D. Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease. J Lab Clin Med. 1973 Nov;82(5):769–775. [PubMed] [Google Scholar]
  14. Piirainen H., Gripenberg M., Laitinen O. Anti-ribonucleoprotein antibodies in inflammatory rheumatic diseases. Scand J Rheumatol. 1984;13(2):177–180. doi: 10.3109/03009748409100383. [DOI] [PubMed] [Google Scholar]
  15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  16. Provost T. T., Talal N., Harley J. B., Reichlin M., Alexander E. The relationship between anti-Ro (SS-A) antibody-positive Sjögren's syndrome and anti-Ro (SS-A) antibody-positive lupus erythematosus. Arch Dermatol. 1988 Jan;124(1):63–71. [PubMed] [Google Scholar]
  17. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  18. Tan E. M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93–151. doi: 10.1016/s0065-2776(08)60641-0. [DOI] [PubMed] [Google Scholar]
  19. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  20. Tan E. M., Fritzler M. J., McDougal J. S., McDuffie F. C., Nakamura R. M., Reichlin M., Reimer C. B., Sharp G. C., Schur P. H., Wilson M. R. Reference sera for antinuclear antibodies. I. Antibodies to native DNA, Sm, nuclear RNP, and SS-B/La. Arthritis Rheum. 1982 Aug;25(8):1003–1005. doi: 10.1002/art.1780250814. [DOI] [PubMed] [Google Scholar]
  21. Westgeest A. A., van den Brink H. G., de Jong J., Swaak A. J., Smeenk R. J. Routine testing for antinuclear antibodies: a comparison of immunofluorescence, counterimmunoelectrophoresis and immunoblotting. J Autoimmun. 1988 Apr;1(2):159–170. doi: 10.1016/0896-8411(88)90023-6. [DOI] [PubMed] [Google Scholar]
  22. Winn D. M., Wolfe J. F., Lindberg D. A., Fristoe F. H., Kingsland L., Sharp G. C. Identification of a clinical subset of systemic lupus erythematosus by antibodies to the SM antigen. Arthritis Rheum. 1979 Dec;22(12):1334–1337. doi: 10.1002/art.1780221203. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES